Table Of Contents:

1. Market Context & Strategic Relevance

 1.1 Opening Context (Why the market matters)

 1.1.1 Why This Market Is Gaining Strategic Attention

     1.1.2 Business Decisions This Report Supports

 1.2 Scope

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Treatment Type

  2.3.2 Market Size By Route of Administration

  2.3.3 Market Size By Distribution Channel

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Active Pharmaceutical Ingredient (API) and Pharmaceutical Raw Material Suppliers

3.4.2 Pharmaceutical and Biotechnology Companies

3.4.3 Pharmaceutical Distributors, Wholesalers, and Specialty Pharmacies

3.4.4 Hospitals, Gastroenterology Clinics, Healthcare Providers, and Patients (End-Users)  

3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

   4.1 Disease Prevalence & Epidemiological Statistics

 4.1.1 Average Increase in Global Primary Sclerosing Cholangitis (PSC) Patient Population (%)

 4.1.2 Percentage Growth in Newly Diagnosed PSC Cases (%)

 4.1.3 Average Increase in PSC Prevalence Across Major Geographic Regions (%)

 4.1.4 Share of PSC Patients Diagnosed with Advanced Liver Disease (%)

 4.1.5 Average Growth in PSC-Associated Inflammatory Bowel Disease Cases (%)

4.2 Diagnosis & Clinical Management Metrics

 4.2.1 Average Increase in PSC Diagnostic Testing and Screening Procedures (%)

 4.2.2 Percentage Growth in Adoption of Advanced Imaging and Diagnostic Technologies (%)

 4.2.3 Average Improvement in Early Detection of PSC Cases (%)

 4.2.4 Share of PSC Patients Receiving Long-Term Disease Monitoring (%)

 4.2.5 Average Growth in Liver Transplant Evaluations Among PSC Patients (%)

4.3 Drug Development & Therapeutic Innovation Statistics

 4.3.1 Percentage Increase in Clinical Trials for PSC Therapeutic Candidates (%)

 4.3.2 Average Growth in R&D Investment for PSC Drug Development (%)

 4.3.3 Share of PSC Clinical Trials Focused on Disease-Modifying Therapies (%)

 4.3.4 Average Increase in Novel Mechanism-Based PSC Treatment Candidates (%)

 4.3.5 Share of PSC Pipeline Therapies Advancing to Late-Stage Clinical Development (%)

4.4 Patient Treatment & Healthcare Utilization Indicators

 4.4.1 Average Increase in PSC-Related Hospitalization Rates (%)

 4.4.2 Percentage Growth in Demand for Supportive PSC Treatment and Disease Management (%)

 4.4.3 Average Increase in Liver Transplant Procedures Associated with PSC (%)

 4.4.4 Share of PSC Patients Receiving Specialized Hepatology Care (%)

 4.4.5 Average Growth in Patient Enrollment in PSC Clinical Research Programs (%)

4.5 Patient Support & Research Ecosystem Metrics

 4.5.1 Percentage Increase in Funding for PSC Research Initiatives (%)

 4.5.2 Average Growth in Rare Disease Awareness and PSC Education Programs (%)

 4.5.3 Share of PSC Research Initiatives Focused on Biomarker Discovery (%)

 4.5.4 Average Increase in Patient Participation in PSC Advocacy and Support Programs (%)

 4.5.5 Share of PSC Research Collaborations Involving Pharmaceutical, Academic, and Clinical Institutions

5. Primary Sclerosing Cholangitis (PSC) Market Segmental Analysis & Forecast, By Treatment Type, 2022–2035, Value (Usd Million)

5.1 Introduction

 5.2 Ursodeoxycholic Acid (UDCA)

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Obeticholic Acid

 5.4 Antibiotics

 5.5 Immunosuppressants

 5.6 Symptomatic Treatment

 5.7 Liver Transplantation

 5.8 Other Treatments

6. Primary Sclerosing Cholangitis (PSC) Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (Usd Million)

    6.1 Introduction

 6.2 Oral

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Intravenous

 6.4 Other Routes

7. Primary Sclerosing Cholangitis (PSC) Market Segmental Analysis & Forecast, By Distribution Channel, 2022–2035, Value (Usd Million)

    7.1 Introduction

 7.2 Hospital Pharmacies

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Retail Pharmacies

 7.4 Online Pharmacies

 7.5 Specialty Pharmacies

8. Primary Sclerosing Cholangitis (PSC) Market Segmental Analysis & Forecast By Region, 2022–2035, Value (Usd Million)

8.1 Introduction

8.2 North America

 8.2.1 Key Trends

 8.2.2 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Treatment Type, 2022–2035

 8.2.3 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Route of Administration, 2022–2035

 8.2.4 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Distribution Channel, 2022–2035

 8.2.5 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Country, 2022–2035

  8.2.5.1 USA

  8.2.5.2 Canada

8.3 Europe

 8.3.1 Key Trends

 8.3.2 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Treatment Type, 2022–2035

 8.3.3 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Route of Administration, 2022–2035

 8.3.4 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Distribution Channel, 2022–2035

 8.3.5 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Country, 2022–2035

  8.3.5.1 Germany

  8.3.5.2 UK

  8.3.5.3 France

  8.3.5.4 Italy

  8.3.5.5 Spain

  8.3.5.6 Russia

  8.3.5.7 Poland

  8.3.5.8 Rest of Europe

8.4 Asia-Pacific

 8.4.1 Key Trends

 8.4.2 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Treatment Type, 2022–2035

 8.4.3 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Route of Administration, 2022–2035

 8.4.4 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Distribution Channel, 2022–2035

 8.4.5 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Country, 2022–2035

  8.4.5.1 China

  8.4.5.2 India

  8.4.5.3 Japan

  8.4.5.4 South Korea

  8.4.5.5 Australia

  8.4.5.6 ASEAN Countries

  8.4.5.7 Rest of Asia-Pacific

8.5 Latin America

 8.5.1 Key Trends

 8.5.2 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Treatment Type, 2022–2035

 8.5.3 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Route of Administration, 2022–2035

 8.5.4 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Distribution Channel, 2022–2035

 8.5.5 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Country, 2022–2035

  8.5.5.1 Brazil

  8.5.5.2 Argentina

  8.5.5.3 Mexico

  8.5.5.4 Colombia

  8.5.5.5 Rest of Latin America

8.6 Middle East & Africa

 8.6.1 Key Trends

 8.6.2 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Treatment Type, 2022–2035

 8.6.3 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Route of Administration, 2022–2035

 8.6.4 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Distribution Channel, 2022–2035

 8.6.5 Primary Sclerosing Cholangitis (PSC) Market Size & Forecast, By Country, 2022–2035

  8.6.5.1 UAE

  8.6.5.2 Saudi Arabia

  8.6.5.3 Qatar

  8.6.5.4 South Africa

  8.6.5.5 Rest of Middle East & Africa

9. Competitive Landscape

 9.1 Key Players' Positioning

 9.2 Competitive Developments

  9.2.1 Key Strategies Adopted (%), By Key Players, 2025

  9.2.2 Year-Wise Strategies & Development, 2022–2025

  9.2.3 Number Of Strategies Adopted By Key Players, 2025

 9.3 Market Share Analysis, 2025

 9.4 Product/Service & Application Benchmarking

  9.4.1 Product/Service Specifications & Features By Key Players

  9.4.2 Product/Service Heatmap By Key Players

  9.4.3 Application Heatmap By Key Players

 9.5 Industry Start-Up & Innovation Landscape

9.6 Key Company Profiles

 9.6.1 Acorda Therapeutics, Inc.

  9.6.1.1 Company Overview & Snapshot

  9.6.1.2 Product/Service Portfolio

  9.6.1.3 Key Company Financials

  9.6.1.4 SWOT Analysis

 9.6.2 Gilead Sciences, Inc.

9.6.3 NGM Biopharmaceuticals, Inc.

9.6.4 Intercept Pharmaceuticals, Inc.

9.6.5 Dr. Falk Pharma GmbH

9.6.6 Allergan Plc.

9.6.7 Shire Plc.

9.6.8 Durect Corporation

9.6.9 Conatus Pharmaceuticals, Inc.

9.6.10 Sirnaomics, Inc.

9.6.11 Shenzhen HighTide Biopharmaceutical Ltd.

9.6.12 CymaBay Therapeutics

9.6.13 Pliant Therapeutics

9.6.14 Immunic AG

9.6.15 Mirum Pharmaceuticals, Inc.

9.6.16 Takeda Pharmaceutical Company Limited

9.6.17 Novartis AG

9.6.18 Bristol Myers Squibb

9.6.19 Madrigal Pharmaceuticals, Inc.

9.6.20 Poxel SA

10. Analyst Recommendations

 10.1 SNS Insider Opportunity Map

 10.2 Industry Low-Hanging Fruit Assessment

 10.3 Market Entry & Growth Strategy

 10.4 Analyst Viewpoint & Suggestions On Market Growth

11. Assumptions

12. Disclaimer

13. Appendix

 13.1 List Of Tables

 13.2 List Of Figures